Issues
-
Cover Image
Cover Image
ABOUT THE COVER
These are overlaid confocal microscopy images of E-cadherin, Actin and DAPI staining in fibronectin-depleted MCF-10A-Ca1h (Ca1h) breast cancer cells. In the article, beginning on page 1579, Shinde and colleagues demonstrate that wild type Ca1h cells are not metastatic, express high amounts of intracellular fibronectin, and display a very mesenchymal phenotype. In contrast, when fibronectin is depleted from the Ca1h cells they undergo a mesenchymal-epithelial transition (as shown) characterized by a return of junctional E-cadherin expression and an enhanced ability to form pulmonary tumors following tail vein injection. As opposed to the tumor promoting role of fibronectin in the extracellular matrix, this study suggests that when epithelial-derived carcinoma cells undergo epithelial-mesenchymal transition, constitutive expression of fibronectin stabilizes their mesenchymal phenotype and inhibits the cell autonomous ability of those cells to complete the final steps of the metastatic process. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Molecular Cancer Research
Table of Contents
Highlights
Rapid Impact
Perspective
Cell Death and Survival
Chromatin, Epigenetics, and RNA Regulation
DNA Damage and Repair
Thymidine Kinase 1 Loss Confers Trifluridine Resistance without Affecting 5-Fluorouracil Metabolism and Cytotoxicity
Genomics
Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations
Oncogenes and Tumor Suppressors
BRCA1-Interacting Protein OLA1 Requires Interaction with BARD1 to Regulate Centrosome Number
Signal Transduction
YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity
Tumor Microenvironment and Immunobiology
Journal Archive
Molecular Cancer Research
(2002-Present; volumes 1-current)Published monthly since November, 2002.
(ISSN 0008-5472)
Cell Growth & Differentiation
(1990-2002; volumes 1-13)Published monthly 1990- September, 2002.
(ISSN 1044-9523)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.